Clinigen targets validated by SBTi, setting verified path to Net-Zero

Science Based Targets initiative validation confirms Clinigen’s targets are 1.5°C aligned, supported by a new data partnership to drive transparency. 

LONDON, UK, 04 December 2025 – Clinigen, the global pathfinder accelerating access to critical medicines, has today announced that its near-term and long-term greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi).  

This validation confirms that Clinigen’s roadmap to reduce scope 1, 2, and 3 emissions is scientifically aligned with the 1.5°C trajectory of the Paris Agreement. 

The pharmaceutical industry faces a critical dual mandate of delivering increasingly complex, life-changing medicines to an aging global population, while urgently addressing its environmental footprint. 

With the health sector responsible for approximately 4.4% of global GHG emissions, and recent data suggesting the pharmaceutical value chain has a higher carbon intensity than the automotive sector, decarbonising the clinical supply chain has become a critical factor in de-risking the product lifecycle.  

Clinigen’s validated science-based targets provides a verifiable pathway for biotech and pharma partners to decouple their clinical and commercial growth from carbon emissions. 

Clinigen has aligned with the SBTi Corporate Net-Zero Standard with the goal of reaching net-zero GHG emissions across the value chain by 2040: 

·                     By 2030, Clinigen will target a 42% reduction across scope 1, 2, and 3 emissions.

·                     By 2040, Clinigen will push for a 90% reduction across all scopes.  

Clinigen is committed to improving data accuracy and transparency to better manage the reduction measures required to meet these targets. To achieve this, the company is partnering with Tracera, an AI-powered ESG data platform, and sustainability partners Seismic.  

Together, they are developing a robust process to track emissions across global operations with greater accuracy, moving beyond reliance on standard industry estimates. The goal is to translate these climate targets into verifiable value for partners. 

Varun Sethi, CEO of Clinigen, said: “As Global Pathfinders, our clients rely on us to navigate complexity, and climate risk is now a central part of that landscape. By validating our SBTi targets, we are ensuring that Clinigen is moving in lockstep with the biopharma industry’s most ambitious sustainability goals. This validation confirms our roadmap is scientifically robust, but it is the actions we take next on this net-zero journey that matter. We are committed to aligning our operations with the climate goals and expectations of our clients, ensuring that Clinigen remains a resilient, responsible partner for the long term.”  

Andy Owen, Vice President of Supply Chain at Clinigen, said: “For our carbon-intensive industry, sustainability has to be a top priority, and we are more driven than ever to lead. This validation sets the direction of travel, but the destination is still a long way off. Net-zero is a complex journey, but one we are fully committed to navigating alongside our partners. Our focus now shifts to execution of our targeted initiatives and the industry partnerships needed to drive real reductions across our value chain.”